AptarGroup ATR Pharma — Restructuring initiatives

Other segment segments

Similar metrics at other companies

PFEBiopharma — Restructuring cost incurred to date

$3.3B+22.2%

PFEBiopharma — Expected restructuring cost

$3.7B+54.2%

TMOLaboratory Products and Biopharma Services — Restructuring and other costs

$33M—

GTESRestructuring expenses

$700K-56.3%

UNHOptum Rx — Restructuring Costs

$97.25M—

TMOLife Sciences Solutions — Restructuring and other costs

$9M—

Questions, answered.

What is AptarGroup's pharma — restructuring initiatives?

AptarGroup (ATR) reported pharma — restructuring initiatives of $5K in Q1 2026.

How has AptarGroup's pharma — restructuring initiatives changed year-over-year?

AptarGroup's pharma — restructuring initiatives decreased by 97.4% year-over-year, from $190K to $5K.

What does pharma — restructuring initiatives mean?

Costs associated with organizational changes, facility consolidations, or workforce reductions within the Pharma business segment. These expenses are typically non-recurring and reflect management's efforts to optimize operational efficiency and align the cost structure with long-term strategic goals.